Ramius Capital
Ramius Capital is a $12 billion hedge fund founded in 1994 by Peter Cohen (former Chairman and CEO of Shearson Lehman Brothers) with Jeffrey Solomon (former CAO and Head of Corporate Development at Republic New York Securities Corp.).
Ramius offers Multi-Strategy and Single Strategy Investment Programs.
Multi-Strategy examples include: convertible arbitrage, merger arbitrage and activist investments, distressed securities, capital structure arbitrage, hedged equity, private convertibles, proprietary mortgages, fixed income arbitrage and structured credit investments.
Single Strategy examples include: Merger Arbitrage, Distressed Securities, Convertible Arbitrage, Deep Value Opportunity, Fundamental Equity Market Neutral, Systematic Global Long/Short Equity, Real Estate Equity, Real Estate Lending, Residential Prime Mortgage Backed CDOs.
-
Unusual 11 Mid-Day Movers 12/14: MTXX, CTDC, EMS, CYPB, GXDX, NTWK Higher; CAPS, EONC, INHX, CSPI, BBY Lower
-
Cypress Biosciences (CYPB) Shares Rocket Higher as Board Rejects Ramius's $6/Share Offer
-
Unusual 11 Mid-Day Movers 12/10: THC, EPCT, JTX, BEC, PZG, CYPB Higher; GAP, ASTM, GMCR, HWD, BGP Lower
-
Morning Movers 12/10: THC, EPCT, BEC, JTX, CYPB, GAGA, EDAP, CYH, CRDC Higher; GAP, ASTM, BGP, GMCR, IRE Lower
-
Ramius Increases Bid for Cypress Bioscience (CYPB) 29% to $5.50/Share
-
Ramius raises offer for Cypress Bioscience (CYPB) from $4.25/share to $5.50/share
-
Ramius extends tender offer to buy Cypress Biosciences (CYPB) to November 10th at midnight
-
Ramius Sends Letter to Independent Directors of Cypress Bioscience (CYPB) in Response to Rejected Offer
-
Cypress Bioscience (CYPB) Rejects Ramius' Unsolicited Bid; Exploring Strategic Options
-
Ramius Sends a Letter to Cypress Bioscience (CYPB) Board; Pleads to Allow Shareholders to Decide the Future of the Company
-
Notable Mergers and Acquisitions of the Day 09/15: MSCC, CYPB, HLIT
-
Morning Movers 09/15: HRBR, SVNT, CYPB Higher; UTA, FBC, NBIX Lower
-
Ramius commences cash tender offer for Cypress Bioscience (CYPB) at $4.25/share
-
Cypress Bioscience (CYPB) Sends Letter to Ramius; Still Considers $4.00/Share Propsal Inadequate
-
Ramius LLC Sends Letter to Cypress Bioscience (CYPB) Board
-
Notable Mergers and Acquisitions of the Day 08/06: CYPB, AIG
-
Cypress Bioscience (CYPB) Board Says Ramius Bid Undervalues Company
-
Cypress Bioscience (CYPB) Confirms $4.00/Share Bid Offer from Ramius LLC
-
Unusual 11 Mid-Day Movers 07/19: ATAC, CYPB, TKS, CSCX, KWK, EBI Higher; ROIAK, KV-A, VCBI, FORD, VVUS Lower
-
Morning Movers 7/19: ATAC, CYPB, TKS, COCO, BPI, APOL Higher; ROIAK, BPI, FORD, VVUS, PETS, DAL Lower
-
Notable Mergers and Acquisitions of the Day 07/19: NOK/MOT, CYPB, ATAC, RICK/VCGH
-
Ramius Announces $4/Share Cash Bid for Cypress Bioscience (CYPB)
-
Ramius offers to buy Cypress Bioscience (CYPB) for $4/share in cash

